PNP Therapeutics®, Inc. is a clinical-stage, biopharmaceutical company engaged in the development of a platform technology and proprietary products for the treatment of cancer. At the center of PNP's Therapeutic System is a patented enzyme (E. coli purine nucleoside phosphorylase) that has been shown to work with a variety of well-characterized nucleoside prodrugs generating active metabolites with high levels of anti-tumor activity. PNP Therapeutics® is the exclusive licensee of a comprehensive collection of patents that broadly and specifically cover the Company's technology. These patents are owned jointly by the UAB Research Foundation and Southern Research Institute of Birmingham, Alabama.